Moderna fully enrolls phase 3 trial for COVID-19 vaccine candidate, with heavy emphasis on traditionally under-represented communities

Oct 22, 2020 - 02:45 PM
COVID19 Web Sized

Moderna Inc., today announced the completion of enrollment for its COVID-19 vaccine phase 3 trial.

The drug maker said that it has confirmed 30,000 participants for an efficacy study of mRNA-1273. Moderna and the National Institute of Allergy and Infectious Diseases developed the candidate, which generated a strong immune response in older adults during its phase 1 clinical trial.

Communities that have historically been under-represented in clinical research and are disproportionately impacted by COVID-19 have significant representation among the trial enrollees. Moderna said the study includes more than 11,000 participants from communities of color, representing 37% of the study population and similar to the diversity of the U.S. at large. This includes more than 6,000 participants who identify as Hispanic or Latinx, and more than 3,000 participants who identify as Black or African American.

Related News Articles

Headline
CDC: Flu activity remains high, COVID-19 increasing while RSV peaks 
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
OSHA ends efforts to establish COVID-19 safety standard 
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
Certain PREP Act liability protections for COVID-19 countermeasures extended through 2029 
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
View the AHA's latest United Against the Flu toolkit celebrating fall
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age 
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
CMS releases final guidance on hospital respiratory data condition of participation reporting requirements 
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…